Mediclinic International (MDC) Price Target Lowered to GBX 550 at Credit Suisse Group

Mediclinic International (LON:MDC) had its price target reduced by Credit Suisse Group from GBX 660 ($8.54) to GBX 550 ($7.12) in a research note released on Thursday. Credit Suisse Group currently has a neutral rating on the stock.

Separately, Barclays lowered their price target on shares of Mediclinic International from GBX 751 ($9.72) to GBX 700 ($9.06) and set an overweight rating for the company in a research report on Tuesday, August 7th. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus target price of GBX 655.86 ($8.49).

Shares of LON MDC opened at GBX 467.80 ($6.06) on Thursday. Mediclinic International has a 1 year low of GBX 495.40 ($6.41) and a 1 year high of GBX 890.18 ($11.52).

The company also recently announced a dividend, which was paid on Monday, July 30th. Shareholders of record on Thursday, June 14th were issued a GBX 4.70 ($0.06) dividend. The ex-dividend date of this dividend was Thursday, June 14th. This is a boost from Mediclinic International’s previous dividend of $3.20. This represents a yield of 0.76%.

Mediclinic International Company Profile

Mediclinic International plc, together with its subsidiaries, operates private hospitals. The company offers acute care, specialist-orientated, and multidisciplinary healthcare services under the Mediclinic and Hirslanden brand names. It operates 49 acute care private hospitals and 2 day clinics in South Africa, and 3 hospitals in Namibia with approximately 8,095 beds; 16 acute care private hospitals with 1,677 beds, as well as 4 clinics in Switzerland; and 6 acute care private hospitals and 31 clinics with 714 beds in the United Arab Emirates.

Read More: What is a Leveraged Buyout (LBO)?

Analyst Recommendations for Mediclinic International (LON:MDC)

Receive News & Ratings for Mediclinic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediclinic International and related companies with's FREE daily email newsletter.

Leave a Reply